Care Capital has closed its third life sciences fund with $300 million. The Princeton-based venture group exceeded its original target by $75 million. Care Capital has a particular focus on late stage biopharma companies. Its portfolio includes Anadys, Inotek and Tercica.
- read this release for more information
PLUS: Tioga Pharmaceuticals has raised an impressive $24 million in its first round of venture capital. The biotech company has plans to advance a new therapy into Phase IIa and IIb for asimadoline, acquired from Merck. Release
ALSO: Japan's CanBas has raised $20 million in new venture funds. Release
AND: Athenix has raised $13 million in its third round. Release